B reast cancer struck K., a distant cousin of mine, at age 42. She underwent initial mastectomy with nodal irradiation and then aggressive chemotherapy after the cancer recurred 11 years later. When chemotherapy could not control her cancer, K.'s oncologist recommended hospice care.
The little information K. shared with me at that time indicated the oncologist had not committed many common mistakes in disclosing terminal cancer. He had not avoided the disclosure altogether, 1 sugarcoated it with ambiguities or euphemisms, or encouraged unrealistic hopes for miraculous cures. Instead, he had discussed candidly the chemotherapy's failure, the cancer's resulting incurability, and K.'s likely short survival. 2 He may have made only one mistake: not checking how well K. understood her terminal diagnosis. We doctors often make that mistake. We reliably differentiate for patients curative and palliative therapies and mention treatment refractoriness in terminal care discussions but rarely check patients' understanding of that information. 2 We simply assume patients will ask for clarification when they need it. Yet many patients do not ask for fear of ''bothering the doctor,'' revealing their ignorance, or hearing unwanted answers. 3 Many misunderstandings likely go uncorrected. 2, 4, 5 K. rejected hospice for reasons I cannot fully explain. She might have disagreed with the oncologist's clinical assessment or distrusted his underlying motives. Or she might have believed that a positive attitude would surely produce a positive outcome, fighting could still defeat the cancer, or God would eventually save her. 6 Such beliefs can convince terminal cancer patients they are destined for miraculous cures. I know for sure K. was a fighter: Her rough-and-tumble, big-city upbringing had taught her to fight bad breaks like this cancer.
Expectations of miraculous cures, however, can drive bad decisions. Refusing to surrender, K. began a quixotic search for her cure. She joined nontraditional cancer support groups, combed internet Web sites for nonmainstream ''treatments,'' and traveled widely to get them: laetrile in Mexico, megavitamins and ''spiritual treatments'' in Brazil, special diets and a course on miracles in California. As each ''treatment'' failed, K. became ever more determined.
K. telephoned me once about a European spa's claims to cure far advanced cancers. I decided at that moment I needed to address her unrealistic hopes for cure. I told her I thought she was terminal and probably had only months to live. I also expressed concern that her search for a cure was consuming precious time, energy, and money. I urged redirecting those limited personal resources to activities she might find more rewarding such as visiting close relatives or planning legacy gifts. My comments were met with a long, chilly silence. K. finally said a curt goodbye and hung up. She never called again. I learned months afterward that she had visited the spa, collapsed on the trip home, and died just days later. To the end, K. had understood her ''terminal cancer'' differently than had her oncologist and I.
The study by Lee and others addresses this frequent problem. 7 Their survey suggests how variably Koreans understand the term ''terminal cancer'': Of all their respondents, 46% understood it to mean primarily that the patient has at most 6 months to live; 21%, that the cancer is refractory to treatment; 19%, that it has recurred or metastasized; and 2.5%, that it is merely advancing locally. No meaningful deviations from these overall percentages occurred among the respondent subgroups of cancer patients, family caregivers, oncologists, or the general public.
These results raise important questions for future research. Some questions apply specifically to Koreans. For example, which factors-demographic, biographical, or clinical-explain Koreans' understandings of ''terminal cancer''? And do Koreans' preferences for cancer disclosure and end-of-life treatment differ according to those understandings? I urge Lee and colleagues to pursue these questions. Still other questions apply to all nationalities and ethnic groups. How well do doctors' explanations of terminal cancer meet patient or family informational needs? 4 What distrust or doubts do patients and family bring to such conversations? 8, 9 And which explanation styles are most effective and least threatening? 10 Furthermore, can patients, health professionals, and others articulate their understandings of ''terminal cancer'' clearly and accurately enough to permit valid comparisons? Do these understandings change with time or circumstance? How? Do additional aids (such as brochures, videos, second opinions, or meetings with similar patients 3 ) help clarify patients' understandings? And which understandings most affect patients' end-of-life treatment preferences and priorities? Do certain understandings affect disease course beyond outcomes explained by treatment alone (for example, by prompting patients to will themselves to die sooner or later than expected)? And can doctors use patients' understandings to individualize terminal care?
Even as these questions await further research, the Lee study bears 2 immediate implications for patient care. First, doctors cannot assume that they, patients, and patients' families all understand ''terminal cancer'' in the same way. In fact, the study indicates how much the understandings vary. Second, because the different understandings surely create confusion, an explicit, standardized definition might help. The fixed choices for ''terminal cancer'' in the study questionnaire suggest elements for such a definition. Two choices (locally advancing and metastatic/recurrent) describe a cancer's progressive pathology. Another choice (treatment refractoriness) indicates a goal for future therapy: that is, comfort, not cure or even control. The other 2 choices (survival less than a few days or weeks, or up to 6 months) give prognoses. The authors favor a standardized definition based primarily on treatment refractoriness and secondarily on progressive disease pathology, functional deterioration (not among the fixed choices), and likely short survival.
This proposed definition provides a good starting point for debating what ''terminal cancer'' should mean but, I believe, does not go far enough to guide patient care. K.'s cancer met 3 of the 4 definitional criteria: It was refractory to all potentially curative treatments, was progressing, and would almost certainly shorten her survival to only a few months. Yet K. firmly believed her cancer would be cured and she would outlive it. She obviously did not understand her terminal cancer by the definition Lee and colleagues propose.
As a general internist who occasionally attends terminal cancer patients, I believe that, when curative treatment reaches its limits, doctors must attend to patients' lives as well as their bodies. 11 Patients and families who hear a terminal cancer diagnosis suddenly face many life-changing medical and nonmedical choices. Terminal cancer as Lee and colleagues define it addresses only the medical choices-identifying and treating bodily disease. I believe a terminal cancer definition must also point toward the important nonmedical choices that determine how patients live out their lives. We doctors must help such patients grasp the wide-ranging implications of the situation and guide them (to the extent patients allow) in setting meaningful, realistic goals for the end of life. 12 Guidance for end-of-life living involves 2 tasks: setting priorities and managing scarce patient resources, especially time and energy. We doctors can provide valuable help with both tasks. We might begin helping patients set end-of-life priorities by asking, What do you most want to do in the limited time you have left? Using past experience with similar patients, we can help patients assess which priorities are realistic and which are not. Next, we might help patients rank order the realistic priorities from most to least important. Patients' values should always predominate here (but many patients freely consider the opinions of important others). 12 Finally, we might suggest how patients can pursue their priorities within the constraints of cancer. Patients may need to know the typical terminal trajectory of cancer including possible future symptoms or disabilities. Mobility, energy, and desire to engage life, for example, often decrease over time. Although this information is sobering, I believe doctors can deliver it without unduly frightening patients. Of course, the process of setting priorities, managing patient resources to accomplish them, and revising them as cancer progresses often needs to extend over multiple visits. It works best when the same doctors follow patients continuously to death. 12 Many terminal cancer patients will welcome our advice and use it. Others (such as K.) will reject it and live out their lives in ways we think unwise. Patient-centered care requires us to offer guidance but always safeguards the final decision for the patient.
